Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the…
WATCHLIST OCT 22 2026 Benzinga PreMarket Gainers (% change and volume) $GIXI $STAK $BHVN $BKYI $TSLL $XXII $SAIQ $LITZ Read our Benzinga Review here: https://t.co/DbZGLBN9ND https://t.co/jiSS7c0oaL
$BHVN ... Biohaven says FDA accepts Vyglxia NDA resubmission in spinocerebellar ataxia for review – 8-K filing (11.75) FDA accepted Biohaven's NDA resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia after the filing included new positive supportive analyses. The…
17 analysts rate BHVN Buy on consensus.
Consensus price target: $21.27 (+44.79% upside from $14.69)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Clark George C. VP, Chief Accounting Officer | Nov 17, 2025 | Purchase | 17,000 | $144.77K |
| Coric Vlad director, Chief Executive Officer | Nov 13, 2025 | Purchase | 333,333 | $2.5M |
| Coric Vlad director, Chief Executive Officer | Nov 13, 2025 | Purchase | 333,333 | $2.5M |
| CHILDS JOHN W director | Nov 13, 2025 | Purchase | 3,333,333 | $25M |
| Bailey Gregory director | Nov 13, 2025 | Purchase | 400,000 | $3M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-738.82M |
| 2024 | $0 | — | $-846.42M |
| 2023 | $0 | — | $-408.17M |
Stock data for BHVN: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics